NCT05621096 - Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

January 20, 2025

Study Completion Date

September 30, 2027

Conditions

DLBCL - Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular LymphomaMediastinal Large B-cell LymphomaIndolent B-Cell Non-Hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma

Interventions

RADIATION

Bridging radiation therapy

Days -20 to -7: Patients will receive 2 fractions of 2 gray (Gy) for a total of 4 Gy received.

BIOLOGICAL

Liso-cel

"Day 0: Patients will receive an infusion of liso-cel CAR T-cell product.~Prior to the liso-cell infusion (Days -5 to -3), patients will receive lymphodepleting chemotherapy using fludarabine 30mg/m2 and cyclophosphamide 300mg/m2 per institutional standard procedures."

RADIATION

Post-infusion radiation

Days 30 to 80: Patients eligible for post-infusion radiation will receive a total dose of up to 32 Gy.

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha